Ayub Hussain, MD
Gastroenterology · Houston, TXNPI 1538279468
Payments from drug & device makers
What this record shows
This record is dominated by gifts: $595 of the $917 with a category attached, or 64.9%. Braintree Laboratories, Inc. accounts for 64.9% of it on its own, with 12 other manufacturers making up the rest. That places this record below the midpoint for gastroenterology clinicians in TX, where the typical reported total is $3,104.
Across 26 payments — averaging $35.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Braintree Laboratories, Inc.$595
- Johnson & Johnson$71
- AbbVie$59
- Covidien LP$38
- Olympus America Inc.$35
- Ambu Inc.$24
- plus $96 from 7 others
Across 31 payments — averaging $11,170 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$278K
- Shire North American Group Inc$43K
- Takeda Pharmaceuticals U.S.A., Inc.$18K
- Pfizer$8K
What the payments were for
- Food & beverage$32235%
- Education$00%
- Gifts$59565%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Braintree Laboratories, Inc. | 9 | $595 |
| Johnson & Johnson(2 entities) | 3 | $71 |
| AbbVie | 3 | $59 |
| Covidien LP | 1 | $38 |
| Olympus America Inc. | 2 | $35 |
| Ambu Inc. | 1 | $24 |
| Merck | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Intercept Pharmaceuticals, Inc. | 1 | $15 |
| Medtronic | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Ferring Pharmaceuticals Inc. | 1 | $11 |
| Romark Laboratories, LC | 1 | $6 |
How this compares
$917 in reported general payments places this provider in the 25th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 246 | $11,132 |
| Entecavir | 18 | $5,315 |
| Omeprazole | 92 | $1,356 |
| Pantoprazole Sodium | 56 | $967 |
| Famotidine | 12 | $230 |
| Lactulose | 19 | $169 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Houston
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Brooks CashHouston$867K
- Mohamed OthmanHouston$777K
- Isaac RaijmanHouston$565K
- Kalpesh PatelHouston$382K
- Victor Ankoma-SeyHouston$340K
- John VierlingHouston$270K
- George TriadafilopoulosHouston$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.